Skip to main content
. 2015 Oct 15;14:141. doi: 10.1186/s12933-015-0305-1

Table 1.

Clinical characteristics

Obesity (n = 427) Non-obesity (n = 698) P
Age, years 63 ± 10 66 ± 10 <0.001
Male 283 (66) 457 (66) 0.783
BMI, kg/m2 27.1 ± 2.0 22.3 ± 1.8 <0.001
Co-existing conditions
 Hypertension 294 (69) 448 (64) 0.109
 Dyslipidemia 134 (31) 169 (24) 0.009
 CKD 110 (26) 232 (33) 0.008
 Previous MI 22 (5) 39 (6) 0.754
Smoking 143 (34) 229 (33) 0.814
STEMI 204 (48) 326 (47) 0.727
LVEF 53 ± 11 50 ± 12 <0.001
Systolic blood pressure, mmHg 130 ± 28 130 ± 28 0.851
Diastolic blood pressure, mmHg 78 ± 17 76 ± 16 0.116
eGFR, mL/min/1.73 m2 76 ± 29 72 ± 33 0.105
DM duration, years 9.8 ± 8.2 11.5 ± 8.5 0.003
Laboratory
 Total cholesterol, mg/dL 178 ± 46 170 ± 46 0.004
 Triglyceride, mg/dL 146 ± 98 131 ± 100 0.022
 LDL, mg/dL 109 ± 40 101 ± 41 0.002
 HDL, mg/dL 44 ± 28 44 ± 17 0.988
 Creatinine, mg/dL 1.2 ± 1.3 1.3 ± 1.4 0.130
 HbA1c, % 7.8 ± 1.4 7.9 ± 1.6 0.370
 hs-CRP, mg/dL 4.6 ± 15.9 6.9 ± 23.9 0.081
 NT-ProBNP, pg/mL 2836 ± 7592 4040 ± 9074 0.096
 Peak CK-MB, ng/mL 82 ± 114 83 ± 137 0.880
 Troponin-I, ng/mL 29 ± 62 31 ± 59 0.637
Medication at discharge, n (%)
 Aspirin 423 (99) 683 (98) 0.126
 Clopidogrel 409 (96) 661 (95) 0.413
 Cilostazol 83 (19) 131 (19) 0.781
 Beta blocker 364 (85) 591 (85) 0.794
 ACEI/ARB 355 (83) 586 (84) 0.720
 Statin 365 (86) 572 (82) 0.123
 Nitrate 111 (26) 205 (29) 0.222
 Nicorandil 77 (18) 149 (21) 0.178
 Insulin 51 (12) 119 (17) 0.020
2-year clinical outcomes, n (%)
 Cardiac death 3 (0.7) 25 (3.6) 0.003
 All-cause death 8 (1.9) 36 (5.2) 0.006

ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, CKD chronic kidney disease, CK-MB creatine kinase-MB, DM diabetes mellitus, eGFR estimated glomerular filtration rate, HbA1c hemoglobin A1c, HDL high density lipoprotein, hs-CRP high sensitivity C-reactive protein, LDL low density lipoprotein, LVEF left ventricular ejection fraction, MI myocardial infarction, STEMI ST-elevation MI